- Home
- ANL vs DXR Comparison
ANL vs DXR Comparison
Compare ANL & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | DXR |
|---|---|---|
| Founded | 2004 | 1970 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 61.1M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANL | DXR |
|---|---|---|
| Price | $1.42 | $12.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 31.4K | 2.9K |
| Earning Date | 04-20-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | N/A | ★ $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $35.77 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.88 | $6.55 |
| 52 Week High | $2.99 | $14.15 |
Technical Indicators
Market Signals| Indicator | ANL | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 52.14 |
| Support Level | $1.42 | $12.38 |
| Resistance Level | $1.70 | $12.67 |
| Average True Range (ATR) | 0.18 | 0.26 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 65.39 | 59.58 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.